New drug combo for advanced EGFR-positive head and neck cancer
Part of Cancer clinical trials.
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a type of head and neck cancer called squamous cell carcinoma that is EGFR positive (a protein found in the tumor).
- The cancer must not have spread to other parts of the body and must be considered advanced but still operable.
- You should be in good overall health, with adequate organ function (like blood counts and liver/kidney function) per study standards.
- You must not have had prior treatment for this cancer (except diagnostic procedures).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial is testing a combination of two drugs (becotatug vedotin and pucotenlimab) given before surgery to shrink recurrent head and neck cancer that has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this approach helps make the tumor removable and improves outcomes.
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
This trial tests a new combination of two drugs for people with advanced head and neck cancer who cannot take standard platinum chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to treat head and neck cancer that has come back in the same area. The goal is to shrink the tumor and help your body's immune system fight the cancer.
Hear when a new Head and Neck Squamous Cell Carcinoma, HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.